TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Researchers from University of Barcelona detail new studies and findings in the area of monoclonal antibodies
April 14th, 2009
A new study, 'Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention,' is now available. "We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined," scientists writing in the European Journal of Clinical Microbiology & Infectious Diseases report. "Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and...
Source: TB & Outbreaks Week (2009-04-14)
|
